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BACKGROUND: Administration of interleukin-2 (IL-2) has shown some effects on malignant pleural mesothelioma (MPM) tumour
regression. The purpose of this study was to investigate the ability of IL-2 to modify immunological effector cells and angiogenesis in
MPM patients and their prognostic value.
METHODS: Tumour-infiltrating lymphocytes (CD4, CD8, Foxp3), mast cells (MCs) (tryptase and chymase), microvessel count (MVC)
and VEGF were determined by immunohistochemistry in two series of MPM patients: 60 patients treated with intra-pleural
preoperative IL-2 and 33 patients untreated.
RESULTS: Tryptase MCs, and CD8 and Foxp3 lymphocytes were significantly increased in the IL-2-treated group, whereas MVC was
significantly lower in the same group. Moreover, in the IL-2-treated group, greater tryptaseþMCs and greater Foxp3 lymphocytes
were associated with improved and poorer clinical outcomes, respectively. Notably, when these two immunological parameters were
combined, they predicted outcomes more effectively.
CONCLUSIONS: This study showed that IL-2 treatment leads to a significant increase of immunological parameters, concomitantly with a
reduction in vasculature, providing new insight into the cancer mechanisms mediated by IL-2. Moreover, these results suggest that
tryptase-positive MCs and Foxp3þ lymphocytes predict clinical outcomes in IL-2-treated patients, highlighting the critical role of the
inflammatory response in mesothelioma cancer progression.
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Malignant pleural mesothelioma (MPM) is a relatively rare tumour
with a growing occurrence in the past few decades throughout the
world. It is a fatal neoplasm, with a median survival of 12 months
in patients receiving palliative care (Robinson et al, 2005).
Presently, there is no satisfactory treatment of MPM, although
recent reports suggest that multimodality therapy, including
surgery, may result in a significant improvement in the survival
of select patients (Rusch et al, 2001; Lucchi et al, 2007).
The precise relationship between the immune system and cancer
is still unknown. The tumour–host interaction has a pivotal role in
tumour progression and involves various cell types present in the
tumour microenvironment, including neoplastic cells, immune
effector cells, stromal cells and extracellular matrix components
(Zou, 2005). The tumour inflammatory infiltrate is composed of
different immune effector cells, such as lymphocytes, macro-
phages, dendritic cells, and mast cells (MCs) (Balkwill and
Mantovani, 2001). Particularly, tumour-infiltrating lymphocytes
(TILs) present in the tumour microenvironment have been
recognised as principal effectors in modulating tumour immunity
(Curiel et al, 2004; Yu and Fu, 2006).
Various studies have shown mesothelioma to be sensitive to
immunotherapy using cytokines in an attempt to stimulate the
anti-tumoural immune response (Robinson et al, 2005).
Interleukin-2 (IL-2) was first described as a pro-inflammatory
cytokine produced by activated T cells whose main action is to
promote proliferation, survival and differentiation of T cells
(Cantrell and Smith, 1984; Rubin, 1993; Akbar et al, 1996;
Armstrong et al, 2001). Intravenous, subcutaneous or intra-pleural
administration of IL-2 has shown some effects on tumour
regression in MPM, supporting the use of IL-2 in clinical trial
settings (Goey et al, 1995; Astoul et al, 1998; Castagneto et al, 2001;
Mulatero et al, 2001; Lucchi et al, 2007). However, the mechanism
underlying the biological effects of IL-2 on tumour growth is
complex and it is still largely unknown.
Interleukin-2 can affect many different cell types, particularly
cytotoxic CD8þ T lymphocytes and regulatory T (Treg) cells.
The latter cells are a subset of CD4þ T lymphocytes defined
by their constitutive expression of the IL-2 receptor a chain
CD25 (Sakaguchi et al, 1996). The nuclei of these cells also contain
the Foxp3 transcription factor that is reported to be a key
regulatory gene for the development and function of Treg cells and
the most specific marker of this type of cells (Hori et al, 2003; Revised 30 September 2009; accepted 19 October 2009
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sFontenot and Rudensky, 2005). Moreover, IL-2 may affect different
cell types, including CD4þ T cells, NK cells, macrophages and B
cells, resulting in anti-tumour immunity (Jackaman et al, 2003).
Interleukin-2 could also activate MCs (Maggiano et al, 1990;
Galli et al, 1993), and induce tumour rejection, inhibiting
tumour-associated vascularity (Jackaman et al, 2003).
The purpose of this study was to evaluate the effect of IL-2 in the
MPM microenvironment and to examine the prognostic value
of changes in immunological effector cells and angiogenesis in
the group of 60 MPM patients who received preoperative IL-2
treatment.
MATERIALS AND METHODS
Patients
A total of 93 patients with MPM were included in this study. The
specimens were obtained from patients who underwent surgical
resection at the Department of Cardio-Thoracic Surgery of the
University of Pisa, from January 1999 to May 2008. Participation in
this study required informed consent. No patient had received
chemotherapy or radiotherapy before surgery. The patients were
divided into two groups: patients who received treatment with
preoperative intra-pleural IL-2 and untreated patients. Sixty
patients, 51 males and 9 females received preoperative immuno-
therapy with intra-pleural IL-2 (18 106UI per day every other
day for three times), according to eligibility criteria and the
treatment protocol described earlier (Lucchi et al, 2007). After 1
day of recovery, the patients underwent a thoracotomy. Of the 60
patients, 53 (88.3%) had a pleurectomy/decortication (P/D),
whereas the remaining 7 patients (11.7%) had an extrapleural
pneumonectomy. Thirty-three patients, 27 men and 6 women
underwent surgical resection without preoperative immuno-
therapy with IL-2 or any other preoperative therapy. All of the
33 patients had a P/D.
Follow-up of IL-2-treated MPM patients
Sixty patients were observed until death or the final date of
analysis (August 2008), with a median follow-up time of 74 months
for living patients (range, 2–113 months). Forty-one (68.3%)
patients relapsed during follow-up: 33 had a local relapse, 7 had
both a local and a systemic relapse, and only 1 patient had a
systemic relapse. At the end of the follow-up period, 15 patients
(25%) were still alive and 45 (75%) had died. Time to progression
and overall survival rates were calculated as the period from
surgery until the date the disease started to worsen (local and/or
systemic recurrences), or date of death (Table 1).
Tumour specimens
All of the tumour samples were formalin-fixed and paraffin-
embedded for microscopic examination. The most representative
paraffin block of tumour was selected for immunohistochemical
analysis. A histological and pathological diagnosis were reviewed
by two pathologists (G Alı ` and G Fontanini), according to the
WHO 2004 histological and immunohistochemical criteria (Travis
et al, 2004). Disagreements concerning the histological diagnosis
were discussed, and after a critical discussion, a mutual agreement
was reached. The surgical–pathological staging was performed
according to the TNM classification by the International Mesothe-
lioma Interest Group (IMIG) (Rusch, 1995).
Immunohistochemistry
Immunohistochemical analyses were performed on 3mm tissue
sections using specific antibodies. Immunoreaction was displayed
using the avidin–biotin–peroxidase complex method. Peroxidase
activity was visualised with diaminobenzidine. Counterstaining
was performed with haematoxylin. The negative controls were
carried out by omitting the primary antibodies. Immunostaining
was done using a Benchmark immunostainer (Ventana, Tucson,
AZ, USA). In all cases, the immunohistochemical evaluation was
performed independently by two pathologists (G Alı ` and G
Fontanini) who were blind to the clinicopathological character-
istics and treatment of the patients.
For the tryptase and chymase immunohistochemical stainings,
sections were incubated with a mouse anti-human tryptase
monoclonal antibody (Chemicon International, Temecula, CA,
USA), used at a 1:1500 dilution, and with a mouse anti-human
chymase monoclonal antibody (Chemicon International), used at a
1:1600 dilution. Immunostaining for tryptase and chymase
was clearly visible as brown deposits within intact MCs and as
highly localised extracellular granular material (Figure 1A). Each
pathologist identified, under low microscopic power ( 10
objective lens and  10 ocular lens), the areas where the MCs
were the most intensely accumulated, and then counted positive
MCs at  200 microscopic fields. The average of their counts in
three fields was calculated as described earlier (Ibaraki et al, 2005).
For TIL-immunohistochemical staining, sections were incubated
with the following antibodies: mouse anti-human Foxp3 mono-
clonal antibody (clone 236A/E7 diluted 1:300; Abcam, Cambridge,
UK) (Figure 1B), mouse anti-human CD8 monoclonal antibody
Table 1 Patients’ characteristics: untreatment and treatment related
Clinicopathologic
characteristics
IL-2-treated patients
(N¼60) n. cases (%)
Untreated patients
(N¼33) n. cases (%)
Age
Range 41–77 years 54–81 years
Median 62.5 years 70.0 years
Gender
Male 51 (85%) 26 (78.8%)
Female 9 (15%) 7 (21.2%)
Histologic subtypes
Epithelioid 46 (76.7%) 25 (75.8%)
Biphasic 9 (15.0%) 3 (9.0%)
Sarcomatoid 5 (8.3%) 5 (15.2%)
IMIG stage
IB 1 (1.7%)
II 15 (25.0%) 16 (48.5%)
III 44 (73.3%) 17 (51.5%)
ECOG performance status
0 8 (13.3%) 6 (18.2%)
1 34 (56.7%) 20 (60.6%)
2 18 (30.0%) 7 (21.2%)
Recurrence (valid n 60)
Yes 41
Local 33
Local+sistemic 7
Sistemic 1
No 19
Overall survival (valid n 60)
Range 2–60 months
Median 13 months
Time to progression (valid n 45)
Range 1–57 months
Median 12 months
Abbreviations: IMIG¼International Mesothelioma interest Group; ECOG¼Eastern
Cooperative Oncology Group.
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s(clone C8/144B, ready to use for the Ventana automated slide
stainer; Ventana) (Figure 1C), and mouse anti-human CD4
monoclonal antibody (clone 1F6 diluted 1:20; Diagnostic
BioSystem, Pleasanton, CA, USA). Each pathologist identified,
under low microscopic power ( 25 objective lens and  10 ocular
lens), the areas where the positive cells were most intensely
accumulated, and then counted the cells at  400 microscopic
fields. The average of their counts in five fields was calculated
as described earlier (Mizukami et al, 2008; Yoshioka et al, 2008).
The microvessel count (MVC) was determined using the anti-
CD34 antibody (Ventana Medical System, ready to use for the
Ventana automated slide stainer) (Figure 1D). Each pathologist
examined the samples and identified the area with the most intense
vascularisation (hot spot) under low microscopic power ( 10
objective lens and  10 ocular lens). In this area, the number of
microvessels were counted and recorded at  400 ( 40 objective
lens and  10 ocular lens).
For the VEGF expression, the sections were incubated with an
anti-VEGF rabbit polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) used at a 1:50 dilution. The expression of
VEGF was evaluated as a percentage of positive cells in a total of at
least 1000 tumour cells (Ciardiello et al, 2001).
Statistical analysis
Statistical analysis required the use of the following tests: a
Student’s t-test for the analysis of the differences between
preoperative IL-2-treated patients vs untreated patients; an
ANOVA to study the association between risk factors and
inflammatory and angiogenetic variables; a Kaplan–Meier test to
estimate survival function, and a Cox proportional-hazard model
for multivariate survival analysis. The analysis was conducted
using R 2.9.1. The level of significance was set at a P-value of less
than 0.05.
RESULTS
Clinicopathological characteristics
Ninety-three patients were enroled in this study. On the basis of
histological features, the tumours were classified as epithelioid in
46 patients (76.7%), biphasic in 9 patients (15%) and sarcomatoid
in 5 patients (8.3%) in the group of patients treated with
preoperative IL-2. Preoperative intra-pleural IL-2 was adminis-
tered to all of the patients without a dose reduction or
interruption. All of the patients experienced a fever during
treatment and required antipyretic medication (acetaminophen).
Out of the 33 mesotheliomas belonging to the group of untreated
patients, 25 (75.8%) were epithelioid, 3 (9%) were biphasic and 5
(15.2%) were sarcomatoid. Other clinicopathological characteris-
tics of the series of patients of both groups are summarised in
Table 1.
Analysis of immunological and angiogenetic parameters
between the two groups of treatment
The differences between the two treatment’s groups, evaluated by
the Student’s t-test, are summarised in Table 2.
Regarding the MCs, the IL-2-untreated group showed a
significantly lower number of the tryptase MCs in comparison
with treated patients’ group (P¼0.04). No differences between the
two groups of patients were observed for the chymase MCs.
Immunohistochemistry revealed an increase in the number of
CD8þ lymphocytes in the preoperative-treated group in compar-
ison with the untreated patients (P¼0.004). Regarding the
CD4þ lymphocytes, the mean value was higher in the group
treated with IL-2 than in the untreated group, but the difference
was not statistically significant. Evaluation of Foxp3þ lympho-
cytes revealed a significant higher number in the treated group
compared with the untreated group (P¼0.02).
Figure 1 Immunohistochemical staining for tryptase-positive mast cells (A), Foxp3-positive lymphocytes (B), CD8-positive lymphocytes (C), and
microvessel count (D) in mesotheliomas. Original magnification,  100.
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sAs regards MVC, the number of microvessels was significantly
lower in the IL-2-treated patients as opposed to untreated patients
(P¼0.0001). On the contrary, no differences between the two
groups of patients were observed for the percentage of VEGFþ
neoplastic cells.
Associations between immunological and angiogenetic
parameters and clinicopathologic characteristics
Correlations between the analysed parameters and the clinico-
pathologic characteristics of patients are summarised in Table 3.
The MVC was significantly associated with the histologic subtypes
of mesothelioma (P¼0.0047), with a higher MVC for sarcomatoid
and biphasic subtypes than for the epithelioid subtype. No other
significant associations were found between the immunological
and angiogenetic parameters and the clinicopathological
parameters.
Prognostic factors in IL-2-treated MPM patients groups
In univariate analyses, the histologic subtypes were significantly
associated with overall and disease-free survival. The sarcomatoid
subtype showed a worse overall survival (P¼0.02) and a shorter
time-to-progression (P¼0.02). No significant association was
found between survival and other clinicopathologic parameters
(Table 4).
Tryptase-positive MC counts were analysed as a dichotomous
variable using the median value to distinguish low (p15) from
high (415) MC counts. A statistically significant association was
found between the tryptase-positive MC counts and both overall
survival (P¼0.02) and time-to-progression (P¼0.01) (Table 4). A
higher tryptase-positive MC count was significantly associated
with a better overall survival and a longer time-to-progression
(Figure 2A and B).
The Foxp3 count was also analysed as a dichotomous variable
using the median value to distinguish tumours with a low or
negative Foxp3 count (p8.2) and tumours with a high Foxp3
count (48.2). Univariate analysis showed that the number of
Foxp3þ cells was significantly correlated with overall survival
(P¼0.000002) and time-to-progression (P¼0.0039) (Table 4). In
fact, high numbers of Foxp3þ lymphocytes were unfavourable to
both survival and recurrence (Figure 2C and D).
To assess whether tryptase-positive MC and Foxp3þ lympho-
cyte counts in the tumours were independent predictors of
survival, a Cox proportional-hazard model was used to carry out
multivariate analysis. After stratifying for gender, age, histology,
performance status and stage, the two variables maintained their
independent prognostic roles (Table 5).
Combination of tryptase-positive MC and
Foxp3þ lymphocyte density
The prognostic influence of the combination of tryptase-positive
MCs and Foxp3þ lymphocytes was then evaluated. Patients were
classified into three groups: I (n¼14), Foxp3þ lymphocytes high
and tryptase-positive MCs low; II (n¼27), both high density or
both low density; and III (n¼15), Foxp3þ lymphocytes low and
tryptase-positive MCs high. Significant differences in overall
survival were found among the three groups (P¼0.00000017)
(Figure 2E). Group III has better overall survival than groups II
and I.
DISCUSSION
The tumour–host interaction involves various cell types present in
the tumour microenvironment and this interaction could have
contradictory effects on tumour progression by either supporting
tumour growth or by preventing tumour development (Coussens
and Werb, 2002; Mantovani et al, 2008).
IL-2 is a cytokine described to promote activated T-cell
proliferation, survival and differentiation (Cantrell and Smith,
1984; Rubin, 1993; Akbar et al, 1996; Armstrong et al, 2001).
Reduced levels of IL-2 have been associated with a lower survival
of metastatic cancer patients (Herberman, 1984; Lissoni et al,
1991), and numerous trials have been performed using IL-2 alone
or in combination with other forms of immunotherapy and
chemotherapy (Grande et al, 2006). Several studies have shown an
anti-tumoural activity of intra-pleural administration of IL-2 for
the treatment of MPM, supporting the use of IL-2 in clinical trials
(Goey et al, 1995; Astoul et al, 1998; Castagneto et al, 2001;
Mulatero et al, 2001; Lucchi et al, 2007). However, the mechanism
underlying the effects of IL-2 in the modification of the MPM
microenvironment is still unknown.
In this study, we observed a significant increase of tryptase MCs
in IL-2 preoperative-treated patients compared with untreated
patients. In a previous study, Maggiano et al (1990) suggested that
human MCs express IL-2 receptors on their surface. Furthermore,
MCs are known to produce and release different cytokines,
including IL-2, promoting the recruitment of immune effector
cells (Galli et al, 1993). Other studies (Panelli et al, 2002; Den Otter
et al, 2008) suggest that the recruitment of immune cells induced
by IL-2 administration at the tumour site could be also because of
an indirect affect of IL-2 through MCs activation.
Regarding the TILs, we observed a statistically significant
increase in both CD8 and Foxp3 lymphocytes in the IL-2 treatment
group. The number of CD4 cells was also increased in the same
group, but this finding was not statistically significant. A recent
study evaluated various lymphocyte subpopulations after intra-
tumoural administration of IL-2 in a murine model of meso-
thelioma (Jackaman et al, 2003). The authors showed that IL-2
administration inhibited tumour growth and prolonged survival
Table 2 Correlations between immunological and angiogenetic para-
meters in the IL-2-treated patients’ group and in the untreated patients’
group
Immunological and
angiogenetic parameters
(mean±s.d.)
IL-2
treatment
No IL-2
treatment P-value
Tryptase 26.18±17.70 19.32±9.05 0.04
Chymase 4.06±5.50 3.40±5.80 0.60
Foxp3 11.80±12.25 6.12±9.90 0.02
CD4 60.33±40.38 47.42±35.00 0.13
CD8 90.83±30.64 67.11±46.57 0.004
CD34 62.12±22.13 147.70±55.09 0.0001
VEGF 33.70±30.95 38.18±35.04 0.64
Abbreviation: IL¼interleukin. Bold values indicate Po0.05.
Table 3 Association of immunological and angiogenetic variables with
clinicopathologic parameters
Features
Tryptase
MCs
Chymase
MCs CD8 CD4 Foxp3 MVC VEGF
P-values
Age 0.77 0.74 0.09 0.63 0.87 0.09 0.97
Gender 0.07 0.98 0.07 0.54 0.14 0.58 0.06
IMIG stage 0.35 0.46 0.06 0.52 0.08 0.06 0.48
Histology 0.98 0.78 0.06 0.96 0.06 0.0047 0.08
PS 0.85 0.26 0.94 0.73 0.07 0.99 0.83
Abbreviations: IMIG¼International Mesothelioma Interest Group; PS¼performance
status; MCs¼mast cells; MVC¼microvessel count. Bold values indicate Po0.05.
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sand that both CD8 and CD4 lymphocytes were required for tumour
regression. CD8 T-cells are known have a pivotal role in mediating
local tumour immunity throughout antigen-specific tumour cell
killing (Zou, 2006). These findings provide a rationale for using
IL-2 to enhance CD8þcytotoxic lymphocyte activity to improve
tumoural regression.
Regulatory T (Treg) cells, a subset of CD4þCD25þFoxp3þ T
lymphocytes, are mediators with the functional ability to
regulate/suppress tumour immunity (Zou, 2006). High levels of
Treg lymphocytes have been observed in malignant tumours
(Chattopadhyay et al, 2005) compared to benign lesions and
normal tissue (Liyanage et al, 2002; Ichihara et al, 2003; Curiel
et al, 2004). In a murine model of mesothelioma (Needham et al.,
2006), intra-tumoural recruitment of Treg lymphocytes constituted
an immune evasion mechanism leading to an increase in tumour
growth. After this, it was proposed that intra-tumoural removal of
Treg cells should lead to increased anti-tumour immunity, and
various attempts have been made to target Tregs lymphocytes as
anti-cancer therapy, with different results (Shimizu et al, 1999; Yu
et al, 2005; Hegmans et al, 2006; Needham et al., 2006). The role of
IL-2 in mediating Treg cell homeostasis is still unclear, although
evidence has suggested a role of IL-2 in promoting the
development and suppressive function of Treg cells (Turka and
Walsh, 2008). Few studies have explored Treg cells in MPM
(DeLong et al, 2005; Hegmans et al, 2006; Anraku et al, 2008).
Anraku et al (2008) found a small number of Treg cells in MPM.
DeLong et al (2005) also reported a lower number of these cells in
the pleural effusions from seven MPM patients, comparing with
those from lung or breast cancer patients. On the contrary,
Hegmans et al (2006) showed a significant numbers of Treg cells in
biopsies from MPM patients, although a small number of cases
(only four cases) were analysed. In our study, we observed a
significantly higher number of positive Treg cells in the group of
IL-2-treated patients compared with untreated patients, confirm-
ing the expansion of the Treg subset observed in patients with
melanoma and renal carcinoma who underwent IL-2 therapy
(Ahmadzadeh and Rosenberg, 2006). Along these lines, the authors
showed that the Treg cell population expanded in vitro after IL-2
administration, showing a strong suppressive function of the anti-
tumour immune response. These findings suggest that depletion of
the Treg subset lymphocytes may enhance the ability of IL-2 to
boost host immunity against cancer.
Several studies have correlated IL-2 therapy with angiogenesis.
They show that CD8 lymphocytes seem to be required for reducing
tumour-associated vascularity (Sakkoula et al, 1997; Jackaman
et al, 2003). In light of these studies, we have also evaluated the
MVC and VEGF expression. MVC was significantly lower in IL-2-
treated patients compared with untreated patients. In the same
way, VEGF expression was lower in IL-2-treated patients, but the
difference with untreated patients was not significant. Our results
support the hypothesis for a role of IL-2 in inhibiting blood vessels
in MPM patients, suggesting a supplementary anti-cancer mechan-
ism that is mediated by IL-2 in this type of tumour.
In our study, we found that non-epithelioid subtypes showed a
significantly higher MVC than those with epithelioid histology and
this finding could be explained by considering that tumours with
sarcomatoid differentiation have more aggressive behaviour and
poorest prognosis (Travis et al, 2004).
In this study, we confirmed that tryptase-positive MCs predict a
better clinical outcome in IL-2-treated patients with MPM (Alı `
et al, 2009). In the same treatment group, we observed that Treg
lymphocytes had a negative impact on the prognosis of patients.
As far as we know, this is the first study in which a statistically
significant correlation was found between Treg lymphocytes and
prognosis in MPM. Anraku et al (2008) found that Treg cells were
negatively correlated with prognosis, but the finding was not
statistically significant. They also showed that high levels of CD8þ
lymphocytes were associated with a better prognosis and with a
lower incidence of mediastinal lymph node metastasis. In our
study, we observed the same correlation of CD8þ lymphocytes
with prognosis in MPM patients treated with IL-2, although it was
not statistically significant.
Interestingly, when counts of tryptase-positive MCs and Treg
cells are combined, the outcome of patients can be predicted more
effectively, confirming the close relationship between these two
immunological parameters (Lu et al, 2006; Ju et al, 2009).
Therefore, tryptase-positive MCs and Treg lymphocytes are
promising prognostic parameters that could be used jointly to
identify groups of patients with distinct outcomes.
Table 4 Univariate analysis of overall survival and time to progression in
MPM patients treated with IL-2
Features
No. of
patients
Overall
survival
P-value
Time to
progression
P-value
Age (41–77 mean 61.8) median 62.5
p62 30
462 30 NS NS
Gender
Male 51 NS NS
Female 9
IMIG stage
IB+II 1+14 NS NS
III 42
Histologic subtypes
Epithelioid 46
Biphasic 9 0.02 0.02
Sarcomatoid 5
ECOG performance status
08
13 2 N S N S
21 7
Tryptase MCs
Low 16 0.02 0.01
High 44
Chymase MCs
Low 33 NS NS
High 27
MVC (CD34)
Low 30 NS NS
High 30
FoxP3
Low 29 0.000002 0.0039
High 29
CD4
Low 24 NS NS
High 24
CD8
Low 29 NS NS
High 28
VEGF
Low 28 NS NS
High 30
Abbreviations: IMIG¼International Mesothelioma Interest Group; ECOG¼Eastern
Cooperative Oncology Group; MCs¼mast cells; MVC¼microvessel count;
MPM¼malignant pleural mesothelioma; NS¼not significant. Bold values indicate
Po0.05.
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intra-pleural IL-2 leads, on one hand to an increase in tryptase-
positive MCs, and in CD8þ and Foxp3þ lymphocytes, and on the
other hand to an inhibition in tumour-associated vascularity.
These findings give new insights into the complex anti-tumoural
mechanisms mediated by IL-2 in malignant mesotheliomas, which
are useful if IL-2 is to be successfully used in the clinical setting.
Further studies are required to confirm the functional properties of
the effector, or regulatory phenotypes, as the anti-cancer effect of
IL-2 could be related to the correct balance between these two
types of immune cells.
Moreover, we propose that counts of tryptase-positive MCs and
Treg lymphocytes may be strong predictors of outcome of MPM
patients treated with IL-2. These findings underline the importance
of the immunologic analysis in the prognostic and therapeutic
approach in patients with pleural mesothelioma. New, tailored
immunotherapeutic trials in selected patients may be an effective
strategy to improve current regimens and prolong survival of this
very aggressive and fatal tumour.
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